These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25294904)

  • 1. Genetic evolution of T-cell resistance in the course of melanoma progression.
    Sucker A; Zhao F; Real B; Heeke C; Bielefeld N; Maβen S; Horn S; Moll I; Maltaner R; Horn PA; Schilling B; Sabbatino F; Lennerz V; Kloor M; Ferrone S; Schadendorf D; Falk CS; Griewank K; Paschen A
    Clin Cancer Res; 2014 Dec; 20(24):6593-604. PubMed ID: 25294904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
    del Campo AB; Kyte JA; Carretero J; Zinchencko S; Méndez R; González-Aseguinolaza G; Ruiz-Cabello F; Aamdal S; Gaudernack G; Garrido F; Aptsiauri N
    Int J Cancer; 2014 Jan; 134(1):102-13. PubMed ID: 23784959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition.
    Del Campo AB; Carretero J; Muñoz JA; Zinchenko S; Ruiz-Cabello F; González-Aseguinolaza G; Garrido F; Aptsiauri N
    Cancer Gene Ther; 2014 Aug; 21(8):317-32. PubMed ID: 24971583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma.
    Paschen A; Arens N; Sucker A; Greulich-Bode KM; Fonsatti E; Gloghini A; Striegel S; Schwinn N; Carbone A; Hildenbrand R; Cerwenka A; Maio M; Schadendorf D
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3297-305. PubMed ID: 16740750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
    Hicklin DJ; Wang Z; Arienti F; Rivoltini L; Parmiani G; Ferrone S
    J Clin Invest; 1998 Jun; 101(12):2720-9. PubMed ID: 9637706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.
    Paschen A; Méndez RM; Jimenez P; Sucker A; Ruiz-Cabello F; Song M; Garrido F; Schadendorf D
    Int J Cancer; 2003 Mar; 103(6):759-67. PubMed ID: 12516095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy.
    Méndez R; Ruiz-Cabello F; Rodríguez T; Del Campo A; Paschen A; Schadendorf D; Garrido F
    Cancer Immunol Immunother; 2007 Jan; 56(1):88-94. PubMed ID: 16622680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocyte-melanoma interaction: role of surface molecules.
    Becker JC; Bröcker EB
    Recent Results Cancer Res; 1995; 139():205-14. PubMed ID: 7597291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA.
    Wang Z; Cao Y; Albino AP; Zeff RA; Houghton A; Ferrone S
    J Clin Invest; 1993 Feb; 91(2):684-92. PubMed ID: 8432869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes.
    Bernal M; Ruiz-Cabello F; Concha A; Paschen A; Garrido F
    Cancer Immunol Immunother; 2012 Sep; 61(9):1359-71. PubMed ID: 22833104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene.
    Chiari R; Foury F; De Plaen E; Baurain JF; Thonnard J; Coulie PG
    Cancer Res; 1999 Nov; 59(22):5785-92. PubMed ID: 10582700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency.
    Zhao F; Sucker A; Horn S; Heeke C; Bielefeld N; Schrörs B; Bicker A; Lindemann M; Roesch A; Gaudernack G; Stiller M; Becker JC; Lennerz V; Wölfel T; Schadendorf D; Griewank K; Paschen A
    Cancer Res; 2016 Aug; 76(15):4347-58. PubMed ID: 27261508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 Therapy.
    Inozume T; Yaguchi T; Ariyasu R; Togashi Y; Ohnuma T; Honobe A; Nishikawa H; Kawakami Y; Kawamura T
    J Invest Dermatol; 2019 Jul; 139(7):1490-1496. PubMed ID: 30684558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.
    Anichini A; Vegetti C; Mortarini R
    Cancer Immunol Immunother; 2004 Oct; 53(10):855-64. PubMed ID: 15175905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.
    Panelli MC; Bettinotti MP; Lally K; Ohnmacht GA; Li Y; Robbins P; Riker A; Rosenberg SA; Marincola FM
    J Immunol; 2000 Apr; 164(8):4382-92. PubMed ID: 10754339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.
    Wu RC; Liu S; Chacon JA; Wu S; Li Y; Sukhumalchandra P; Murray JL; Molldrem JJ; Hwu P; Pircher H; Lizée G; Radvanyi LG
    Clin Cancer Res; 2012 May; 18(9):2465-77. PubMed ID: 22307139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines.
    Anichini A; Scarito A; Molla A; Parmiani G; Mortarini R
    J Immunol; 2003 Aug; 171(4):2134-41. PubMed ID: 12902520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
    Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
    Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.
    Kawakami Y; Wang X; Shofuda T; Sumimoto H; Tupesis J; Fitzgerald E; Rosenberg S
    J Immunol; 2001 Feb; 166(4):2871-7. PubMed ID: 11160356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.